Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CECIBO: Bosentan in Sudden Blindness Due to Giant Cell Arteritis
NCT03841734Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2020
- Primary completion
- Jul 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bosentan in giant cell arteritis (GCA), blindness, sponsored by Centre Hospitalier Universitaire de Nice. Started Feb 2020; status: completed.
02
Drugs
bosentan
03
Conditions
giant cell arteritis (GCA)blindness
Beyond the preview
Go deeper on NCT03841734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841734.